Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness Through Virus-Host Genetic Combinations

Author:   Tibor Bakacs, MD, PhD, DSc (Chief Scientific Officer of HepC Inc and Pret Therapeutics Ltd.; Consultant, Department of Probability, Alfred Renyi Institute of Mathematics, Hungary)
Publisher:   Elsevier Science Publishing Co Inc
ISBN:  

9780443291647


Pages:   200
Publication Date:   01 October 2025
Format:   Paperback
Availability:   Not yet available   Availability explained
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Our Price $462.00 Quantity:  
Pre-Order

Share |

Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness Through Virus-Host Genetic Combinations


Overview

Leveraging Viruses for the Treatment of Viral Diseases and Cancer: Improving Host Fitness by Combinations of Virus and Host Genes gives a comprehensive overview on the impact of using naturally or intentionally attenuated viruses - which are apathogenic to people - to control viral diseases and cancer. It examines the potential of exploiting, developing, and using apathogenic viruses as therapeutic tools. Sections cover the COVID-19 pandemic and the need for a post-Infection Plan B to combat SARS-CoV-2 infections as gaps in testing and vaccination create the perfect conditions for a new variant of concern to emerge. More generally, the book also provides specific examples of the use of apathogenic viruses to treat other infectious diseases. It discusses the process of manufacturing viral therapies and how infectious disease treatments can be repurposed to improve other therapies like for cancer. With contribution from an international group of contributors, Leveraging Viruses for the Treatment of Viral Diseases and Cancer is useful references for those engages in study and development of infectious diseases and ways to combat them.

Full Product Details

Author:   Tibor Bakacs, MD, PhD, DSc (Chief Scientific Officer of HepC Inc and Pret Therapeutics Ltd.; Consultant, Department of Probability, Alfred Renyi Institute of Mathematics, Hungary)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
Weight:   0.450kg
ISBN:  

9780443291647


ISBN 10:   0443291640
Pages:   200
Publication Date:   01 October 2025
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Forthcoming
Availability:   Not yet available   Availability explained
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Table of Contents

1. The Impact of Viral Creativity on the Evolution of Cellular Genes 2. Our Antiviral Defense Comes from Viruses 3. Exploiting Viral Interference for Therapy 4. Fighting Fire with Fire: Vaccine Viruses to Control Viral Diseases 5. A Post-Infection Plan B to Complement COVID-19 Vaccination 6. Live Viral Vaccines Can Temporarily Protect Against COVID-19 7. Reduced Mortality Among HIV Infected Patients Coinfected with a Common Human Virus 8. Breakthrough Infection can be Achieved in the Presence of Neutralizing Antibodies by Multiple Administrations of Viruses 9. Safety and Regulatory Hurdles of Viral Therapy 10. Simplicity and Affordability of Manufacturing the Infectious Bursal Disease Virus (IBDV) 11. Three Out Of Four New Diseases are Zoonotic: Neglected Pandemic Threats in the United States 12. The Impact of Conventional Acyclovir Complemented with Immunostimulatory IBDV on the Crusting Time of Shingles 13. Combination of IBDV With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus Infections 14. Need for Further Research Providing Cheap and Effective Therapies for COVID-19 15. Repurposing Infectious Diseases Vaccines to Improve Cancer Therapy

Reviews

Author Information

Dr. Tibor Bakacs has 40 years of experience in scientific research. His current interests are (i) viral superinfection treatment (SIT) of hepatitis B and C virus infected patients with unmet needs; (ii) oncolytic Newcastle Disease virus (NDV) therapy of advanced cancer; (iii) therapeutic application of autoimmune T-cells, which are induced by an off-label low-dose immune checkpoint blockade in advanced cancer. Formerly, he was the Head of Immunology at the Hungarian National Institute of Oncology. He spent longer periods abroad, at the Karolinska Institute in Stockholm, Sweden, Christie Hospital in Manchester, UK and the National Cancer Institute (NCI/NIH) in the USA. Currently, he is the Chief Scientific Officer of Superinfection, Pret Therapeutics Ltd, and Lodoco Clinical Ltd. He is also a consultant at the Department of Probability, Alfred Renyi Institute of Mathematics. Dr. Bakacs authored 75 scientific papers and has two patents.

Tab Content 6

Author Website:  

Countries Available

All regions
Latest Reading Guide

ARG20253

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List